Publications (77) Juan Jose Gascon Canovas publications

filter_list

2025

  1. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases

    Clinical Rheumatology

  2. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: “early therapeutic drug monitoring of adalimumab”

    Clinical Rheumatology, Vol. 44, Núm. 3, pp. 1009-1018

  3. Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes

    Gastroenterologia y Hepatologia

  4. STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF–treated patient

    British Journal of Clinical Pharmacology

2023

  1. The Impact of the Magnitude of the Group of Bullies on Health-Related Quality of Life and Academic Performance Among Adolescents

    Child Psychiatry and Human Development, Vol. 54, Núm. 3, pp. 796-805

  2. Willingness to get vaccinated with the first-generation vaccines against SARS-CoV-2

    Public Health Nursing, Vol. 40, Núm. 1, pp. 1-8

2022

  1. Riesgo de infecciones en pacientes con psoriasis en tratamiento con terapias biológicas (anti il-17 y anti il-23): una revisión sistemática con metaanálisis

    XL Reunión Anual de la Sociedad Española de Epidemiología (SEE) y XVII Congresso da Associação Portuguesa de Epidemiología (APE)

  2. The impact of resilience as a protective factor on Health-Related Quality of Life’s psychological dimensions among adolescents who experience peer victimization

    Scientific Reports, Vol. 12, Núm. 1

2020

  1. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease

    International Journal of Clinical Pharmacy, Vol. 42, Núm. 2, pp. 500-507

  2. Precisión diagnóstica de la determinación de la presión arterial en consulta en el control del hipertenso: Propuesta de nuevos valores de corte

    Semergen: revista española de medicina de familia, Núm. 2, pp. 81-89

  3. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients

    Revista Espanola de Enfermedades Digestivas, Vol. 112, Núm. 8, pp. 590-597

  4. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease ORIGINAL PAPERS

    Revista Espanola de Enfermedades Digestivas, Vol. 112, Núm. 5, pp. 360-366

2019

  1. Efficiency between the different measurement patterns of home blood pressure monitoring in the follow-up of hypertensive patients in primary care

    Atencion Primaria, Vol. 51, Núm. 4, pp. 208-217

  2. Incorporation of direct-acting oral anticoagulants to available therapeutic arsenal: Progress adequately?

    Atencion Primaria

  3. Potential and clinical relevant drug-drug interactions among elderly from nursing homes: A multicentre study in Murcia, Spain

    Ciencia e Saude Coletiva, Vol. 24, Núm. 5, pp. 1895-1902

  4. Validity of self blood pressure measurement in the control of the hypertensive patient: Factors involved

    BMC Cardiovascular Disorders, Vol. 19, Núm. 1

2018

  1. Conocimientos, creencias y actitudes de la población gitana ante el cribado del cáncer colorrectal

    Gaceta Sanitaria, Vol. 32, Núm. 1, pp. 11-17

  2. Hemorragia digestiva y prescripción potencialmente inadecuada de AINEs en mayores de 65 años

    Revista espanola de salud publica, Vol. 92

  3. Identifying potentially inappropriate prescriptions in patients over 65 years-old using original Beers criteria and their Spanish adaptation

    Atencion Primaria, Vol. 50, Núm. 2, pp. 88-95

2017

  1. Beers versus STOPP criteria and the possible implications of the Beers criteria's Spanish adaptation

    Farmacia Hospitalaria